
    
      Each SSc patients (n=72) received sirolimus or placebo (active group: placebo group =1:1,
      2mg/dayï¼Œ oral administration, (SIR 2mg, po., Qd) .

      The end points were the changement of modified RSS and the adverse events or severe adverse
      events onset.
    
  